Quantcast

Latest PDE5 inhibitors Stories

2010-06-24 06:30:00

CRANBURY, N.J., June 24 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) today announced the completion of patient dosing and database lock in a double-blind, placebo-controlled, multiple dose, crossover study of bremelanotide, its subcutaneously administered melanocortin agonist for treatment of erectile dysfunction (ED). Palatin expects to report top-line data in the next calendar quarter. The endpoints in the study are evaluation of plasma exposure and blood...

fb905fc98aa63cd7e7d7349aa679b00b1
2010-06-17 06:35:00

The drug industry's latest attempt to find a female equivalent to Viagra fell short in two separate studies, according to federal regulators on Wednesday. The Food and Drug Administration is considering Boehringer Ingelheim's drug flibanserin for pre-menopausal women who experienced a lack in sexual desire, a market that drug makers have been targeting for years since the epic success of Viagra for men. The hunt for a female version of Viagra has proved elusive though, with many drugs...

2010-06-07 06:00:00

MOUNTAIN VIEW, Calif., June 7 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced positive results from the phase 3 REVIVE-Diabetes (TA-302) study, evaluating the safety and efficacy of the investigational drug avanafil for the treatment of erectile dysfunction (ED) in men with type 1 and type 2 diabetes. The REVIVE-Diabetes study met all three primary endpoints across the two doses studied by demonstrating statistically significant improvement in erectile function as...

2010-06-04 07:00:00

MOUNTAIN VIEW, Calif., June 4 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced that VIVUS management will present an overview of the company at three investment conferences during the month of June. The conference presentation schedule is as follows: The 9(th) Annual Needham Healthcare Conference Presented by: Timothy Morris, chief financial officer June 9, 2010 at 2:40 p.m. EDT The Palace...

2010-06-01 17:25:00

MOUNTAIN VIEW, Calif., June 1 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced that data from the previously reported phase 3 pivotal REVIVE (TA-301) study, evaluating the safety and efficacy of the investigational drug avanafil for the treatment of erectile dysfunction (ED), were presented at the American Urological Association (AUA) 2010 Annual Meeting. The data, "Avanafil for the Treatment of Erectile Dysfunction: Results of a Phase 3, Multi-Center, Randomized,...

2010-05-28 06:00:00

MOUNTAIN VIEW, Calif., May 28, /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced that phase 3 data on avanafil, a next generation oral phosphodiesterase type 5 (PDE5) inhibitor therapy being investigated for the treatment of erectile dysfunction (ED), will be presented next Tuesday at the American Urological Association (AUA) 2010 Annual Meeting in San Francisco, California. Irwin Goldstein, M.D., clinical professor of surgery at the University of California, San Diego,...

f71b917e3e389ca467d7fb98f69cf3d61
2010-05-18 11:36:35

Research by a University of Alabama at Birmingham (UAB)  professor shows an association between hearing loss and the use of the erectile dysfunction drug Viagra. Findings published May 18 in Archives of Otolaryngology-Head and Neck Surgery indicate a potential for long-term hearing loss following use of Viagra, and possibly following use of other phosphodiesterase type 5 inhibitors (PDE-5i) drugs such as Cialis and Levitra, although results on those drugs are inconclusive. "It appears...

2010-04-29 06:00:00

MOUNTAIN VIEW, Calif., April 29 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced that Timothy Morris, chief financial officer, will present an overview of the company at the Deutsche Bank 35th Annual Healthcare Conference. The VIVUS presentation will take place at the InterContinental Boston in Boston, Massachusetts on Wednesday, May 5, 2010 at 9:20 a.m. ET. A live webcast and 30-day archive of the presentation will be available at http://ir.vivus.com. About VIVUS...

2010-04-01 07:00:00

MOUNTAIN VIEW, Calif., April 1 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced that Timothy Morris, chief financial officer, will present an overview of the company at BioCentury's 17th Annual Future Leaders in the Biotech Industry Conference. The VIVUS presentation will take place at the Millennium Broadway Hotel in New York, NY on Thursday, April 8, 2010 at 4:00 p.m. ET. A live webcast and 30-day archive of the presentation will be available at http://ir.vivus.com....

2010-03-31 07:00:00

MOUNTAIN VIEW, Calif., March 31 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced that it has terminated the Development and Commercialization Agreement with FemPharm Pty Ltd. (a wholly owned subsidiary of Acrux Limited) for Luramist(TM), a metered dose transdermal application of testosterone for women. The Agreement with FemPharm was originally signed in 2004 along with the agreement to develop Evamist, a metered dose transdermal estradiol spray for menopause. The...


Word of the Day
mundungus
  • A stinking tobacco.
  • Offal; waste animal product; organic matter unfit for consumption.
This word comes from the Spanish 'mondongo,' tripe, entrails.